Bardet‐Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction
Diabetes, Obesity and Metabolism · 2024-04 · 26 (S2) · 13-24
DOI: 10.1111/dom.15480 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2024-02. Verfasst von Jeremy W Tomlinson. Beteiligte Einrichtung: Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, U…. Hauptthemen laut MEDLINE: Bardet-Biedl Syndrome, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: Medical Research Council, Wellcome Trust, NIHR Oxford Biomedical Research Centre.
Abstract (Originalsprache)
Bardet‐Biedl syndrome (BBS) is a rare, monogenic, multisystem disorder characterized by retinal dystrophy, renal abnormalities, polydactyly, learning disabilities, as well as metabolic dysfunction, including obesity and an increased risk of type 2 diabetes. It is a primary ciliopathy, and causative mutations in more than 25 different genes have been described. Multiple cellular mechanisms contribute to the development of the metabolic phenotype associated with BBS, including hyperphagia as a consequence of altered hypothalamic appetite signalling as well as alterations in adipocyte biology promoting adipocyte proliferation and adipogenesis. Within this review, we describe in detail the metabolic phenotype associated with BBS and discuss the mechanisms that drive its evolution. In addition, we review current approaches to the metabolic management of patients with BBS, including the use of weight loss medications and bariatric surgery. Finally, we evaluate the potential of targeting hypothalamic appetite signalling to limit hyperphagia and induce clinically significant weight loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.
ORCID-Profile: Jeremy W Tomlinson
Förderung
- Medical Research Council
- Wellcome Trust
- NIHR Oxford Biomedical Research Centre
Zitieren
APA
Tomlinson, J. W. (2024). Bardet‐Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction. Diabetes, Obesity and Metabolism, 26(S2), 13-24. https://doi.org/10.1111/dom.15480
Vancouver
Tomlinson JW. Bardet‐Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024;26(S2):13-24. doi:10.1111/dom.15480
BibTeX
@article{Tomlinson2024,
author = {Tomlinson, Jeremy W},
title = {Bardet‐Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {S2},
pages = {13--24},
doi = {10.1111/dom.15480}
}
EUVIMED